A new antibiotic complex of six aureolic acids was isolated from the marine sediment-associated strain Streptomyces sp. KMM 9048. Four of the compounds (3–6) were found to be similar but not identical to the known chromomycins A2, A3, demethyl chromomycin A3 and A4. The two remaining compounds, A2–1 (1) and A3–1 (2), were established as novel chromomycin analogs, which did not contain sugar B. Spectroscopic methods including 1D and 2D NMR, and HRMS and MS/MS were applied for structure elucidation. Compounds 1-5 showed strong antimicrobial activity against Gram-positive indicatory bacteria Enterococcus faecium, Staphylococcus aureus, S. epidermidis, and Bacillus subtilis. Antitumor assay indicated that all tested compounds, in different manners, inhibited colony formation of RPMI-7951 and SK-Mel-28 cancer cells. This is the first study reporting the inhibitory effects of chromomycin analogs 1–5 on the colony formation of the investigated cancer cell lines. Compound 3, in a concentration of 5 nM, inhibited colony formation of RPMI-7951 and SK-Mel-28 cells by 82 % and 72 %, respectively. Our finding indicated that, of the compounds tested, 3 and 4 are promising anticancer and antimicrobial agents.
DebbabA, AlyAH, LinWH, ProkschP. (2010) Bioactive compounds from marine bacteria and fungi. Microbial Biotechnology, 3, 544–563.
3.
BullAT, StachJE. (2007) Marine actinobacteria: new opportunities for natural product search and discovery. Trends in Microbiology, 15, 491–499.
4.
ManivasaganP, KangKH, SivacumarK, Li-ChanCY, OhHM, KimSK. (2014) Marine actinobacteria: an important source of bioactive natural products. Environmental Toxicology and Pharmacology, 38, 172–188.
5.
DharmarajS. (2010) Marine Streptomyces as a novel source of bioactive substances. World Journal of Microbiology Biotechnology, 26, 2123–2139.
6.
RemersWA. (1979) The chemistry of antitumor antibiotics, 2. Wiley-Interscience, Chichester, pp. 133–175.
7.
SkarbekJD, SpeedieMK. (1981) Antitumor compounds of natural origin. Chemistry and Biochemistry, 1, 191–235.
8.
BakhasvaGP, BerlinYA, BoldyrevaEF, ChunrunovaOA, KolosovMN, SoiferVS, VasiljevaTE, YartsevaIV. (1968) The structure of aureolic acid (mithramycin). Tetrahedron Letters, 32, 3595–3598.
9.
WohlertSE, KünzelE, MachinekR, MéndezC, SalasJA, RohrJ. (1999) The structure of mithramycin reinvestigated. Journal of Natural Products, 62, 119–121.
10.
BerlinYA, EsipovSE, KolosovMN, ShemyakinMM. (1966) The structure of the olivomycin-chromomycin antibiotics. Tetrahedron Letters, 15, 1643–1647.
11.
MiyamotoM, KawamatsuY, KawashimaK, ShinoharaM, NakanishiK. (1966) The full structures of three chromomycins, A2, A3 and A4. Tetrahedron Letters, 7, 545–552.
12.
YoshimuraY, KoenumaM, MatsumotoK, ToriK, TeruiY. (1988) NMR studies of chromomycins, olivomycins, and their derivatives. Journal of Antibiotics, 41, 53–67.
13.
OgawaH, YamashitaY, KatahiraR, ChibaS, IwasakiT, AshizawaT, etal. (1998) UCH9, a new antitumor antibiotic produced by Streptomyces: I. Producing organism, fermentation, isolation and biological activities. Journal of Antibiotics, 51, 261–266.
14.
KatahiraR, UosakiY, OgawaH, YamashitaY, NakanoH, YoshidaM. (1998) UCH9, a new antitumor antibiotic produced by Streptomyces. II. Structure elucidation of UCH9 by mass and NMR spectroscopy. Journal of Antibiotics, 51, 267–274.
15.
JayasuriyaH, LinghamRB, GrahamP, QuaminaD, HerranzL, GenilloudO, GagliardiM, DanzeisenR, TomassiniJE, ZinkDL, GuanZ, SinghSB. (2002) Durhamycin A, a potent inhibitor of HIV tat transactivation. Journal of Natural Products, 65, 1091–1095.
16.
HuY, Espindola Ana PaulaDM, StewartNA, WeiS, PosnerBA, MacMillanJB. (2011) Chromomycin SA analogs from a marine-derived Streptomyces sp. Bioorganic & Medicinal Chemistry, 19, 5183–5189.
17.
LuJ, MaY, LiangJ, XingY, XiT, LuY. (2012) Aureolic acids from a marine-derived Streptomyces sp. WBF16. Microbiological Research, 167, 590–595.
18.
ToumeK, TsukaharaK, ItoH, AraiMA, IshibashM. (2014) Chromomycins A2 and A3 from marine actinomycetes with TRAIL resistance-overcoming and Wnt signal inhibitory activities. Marine Drugs, 12, 3466–3476.
DewickPM. (1997) Medicinal natural products: a biosynthetic approach. John Wiley and Sons, Inc., New York, pp. 123–124.
21.
CalabresiP, ChabnerBA. (1991) The pharmacological basis of therapeutics. In The pharmacological basis of therapeutics, RallTW, NiesAS, TaylorP. (Eds), Pergamon Press, New York, pp. 1209–1263.
22.
RemsingLL, GonzalezAM, Nur-e-AlamM, Fernandez-LozanoMJ, BranaAF, RixU, OliveiraMA, MendezC, SalasJA, RohrJ. (2003) Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. Journal of the American Chemical Society, 125, 5745–5753.
23.
NúñezLE, NyboSE, González-SabínJ, PérezM, MenéndezN, BrañaAF, ShaabanKA, HeM, MorísF, SalasJA, RohrJ, MéndezC. (2012) A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis. Journal of Medicinal Chemistry, 55, 5813–5825.
24.
TevyashovaAN, ShtilAA, OlsufyevaEN, LuzikovaYN, ReznikovaMI, DezhenkovaLG, IsakovaEB, BukhmanVM, DurandinNA, VinogradovAM, KuzminVA, PreobrazhenskayaMN. (2011) Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics. Bioorganic & Medicinal Chemistry, 19, 7387–7393.
25.
Fernάndez-GuizάnA, MansillaS, BarcelóF, VizcaínoC, NńñzL-E, MorísF, GonzάlezS, PortugalJ. (2014) The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription. Chemico-Biological Interactions, 219, 123–132.
26.
KoenumaM, UchidaN, YamaguchiK, KawamuraY, MatsumotoK. (1988) New aureolic acid antibiotics. I. Screening, isolation, characterization and biological properties. Journal of Antibiotics, XLI, 45–52.
27.
KoenumaM, YoshimuraY, MatsumotoK, TeruiY. (1988) New aureollic acid antibiotics. II. Structure determination. Journal of Antibiotics, XLI, 68–71.
SchmitzH, ClaridgeA. (1977) Biotransformation of antitumor agents by a strain of Whetzelinia sclerotiorum. Journal of Antibiotics, 30, 635–637.
30.
KawanoT, HidakaT, FurihataK, MochizukiJ, NakayamaH, HayakawaY, SetoH. (1990) Isolation and structures of mono- and di-deacetyl chromomycin antibiotics 02–3D and 02–3G from Streptomyces avellaneus. Journal of Antibiotics, XLIII, 110–113.
31.
PettitGR, TanR, PettitRK, DoubekDL, ChapuisJ-C, WeberCA. (2015) Antineoplastic agents 596. Isolation and structure of chromomycin A5 from a Beaufort Sea microorganism. Royal Society of Chemistry Advances, 5, 9116–9122.
32.
WuXC, ChenWF, QianCD, LiO, LiP, WenYP. (2007) Isolation and identification of newly isolated antagonistic Streptomyces sp. strain AP19–2 producing chromomycins. Journal of Microbiology, 45, 499–504.
33.
RomanenkoLA, UchinoM, KalinovskayaNI, MikhailovVV. (2008) Isolation, phylogenetic analysis and screening of marine mollusc-associated bacteria for antimicrobial, hemolytic and surface activities. Microbiological Research, 163, 633–644.
34.
ColburnNH, WendelEJ, AbruzzoG. (1981) Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proceedings of the National Academy of Sciences of the USA, 78, 6912–6916.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
